External validation of the RIETE and SOME scores for occult cancer in patients with venous thromboembolism: a multicentre cohort study.
Early detection of cancer
Occult cancer
RIETE score
SOME score
Screening
Venous thromboembolism
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
09 May 2024
09 May 2024
Historique:
received:
23
03
2024
accepted:
24
04
2024
medline:
10
5
2024
pubmed:
10
5
2024
entrez:
9
5
2024
Statut:
aheadofprint
Résumé
Venous thromboembolism (VTE) may be the first sign of an undiagnosed cancer. The RIETE and SOME scores aim to identify patients with acute VTE at high risk of occult cancer. In the present study, we evaluated the performance of both scores. The scores were evaluated in a retrospective cohort from two centers. The area under the receiver-operating characteristics curve (AUC) evaluated the discriminatory performance. The RIETE score was applied to 815 patients with provoked and unprovoked VTE, of whom 56 (6.9%) were diagnosed with cancer. Of the 203 patients classified as high-risk, 18 were diagnosed with cancer, representing 32.1% (18/56) of the total cancer diagnoses. In the group of 612 low-risk patients, 67.9% of the cancer cases were diagnosed (38/56). Sensitivity, specificity, negative and positive predictive values, and AUC were 32%, 76%, 94%, 9%, and 0.430 (95% confidence interval [CI], 0.38‒0.47), respectively. The SOME score could be calculated in 418 patients with unprovoked VTE, of whom 33 (7.9%) were diagnosed with cancer. Of the 45 patients classified as high-risk, three were diagnosed with cancer, representing 9.1% (3/33) of the total cancer diagnoses. In the group of 373 low-risk patients, 90.9% of the cancer cases were diagnosed (30/33). Sensitivity, specificity, negative and positive predictive values, and AUC were 33%, 88%, 94%, 20%, and 0.351 (95% CI, 0.27‒0.43), respectively. The performance of both scores was poor. Our results highlight the need to develop new models to identify high-risk patients who may benefit from an extensive cancer screening strategy.
Identifiants
pubmed: 38724825
doi: 10.1007/s12094-024-03500-w
pii: 10.1007/s12094-024-03500-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
Références
Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017;117(02):219–30. https://doi.org/10.1160/TH16-08-0615 .
doi: 10.1160/TH16-08-0615
pubmed: 27882374
Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost. 2017;117(01):57–65. https://doi.org/10.1160/TH15-08-0686 .
doi: 10.1160/TH15-08-0686
pubmed: 27709226
Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med. 2008;149(05):323–33. https://doi.org/10.7326/0003-4819-149-5-200809020-00007 .
doi: 10.7326/0003-4819-149-5-200809020-00007
pubmed: 18765702
Gheshmy A, Carrier M. Venous thromboembolism and occult cancer: impact on clinical practice. Thromb Res. 2016;140(Suppl 1):S8–11. https://doi.org/10.1016/S0049-3848(16)30091-3 .
doi: 10.1016/S0049-3848(16)30091-3
pubmed: 27067984
Carrier M, Lazo-Langner A, Shivakumar S, Tagalakis V, Zarychanski R, Solymoss S, SOME Investigators, et al. Screening for occult cancer in unprovoked venous thromboembolism. N Engl J Med. 2015;373(8):697–704. https://doi.org/10.1056/NEJMoa1506623 .
doi: 10.1056/NEJMoa1506623
pubmed: 26095467
Prandoni P, Bernardi E, Valle FD, Visonà A, Tropeano PF, Bova C, et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Semin Thromb Hemost. 2016;42(8):884–90. https://doi.org/10.1055/s-0036-1592335 .
doi: 10.1055/s-0036-1592335
pubmed: 27764880
Coyle K, Carrier M, Lazo-Langner A, Shivakumar S, Zarychanski R, Tagalakis V, et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thromb Res. 2017;151:67–71. https://doi.org/10.1016/j.thromres.2017.01.007 .
doi: 10.1016/j.thromres.2017.01.007
pubmed: 28160670
Robin P, Le Roux PY, Planquette B, Accassat S, Roy PM, Couturaud F, MVTEP Study Group, et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncol. 2016;17(2):193–9. https://doi.org/10.1016/S1470-2045(15)00480-5 .
doi: 10.1016/S1470-2045(15)00480-5
pubmed: 26672686
Piccioli A, Lensing AWA, Prins MH, Falanga A, Scannapieco GL, Ieran M, et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost. 2004;2:884–9. https://doi.org/10.1111/j.1538-7836.2004.00720.x .
doi: 10.1111/j.1538-7836.2004.00720.x
pubmed: 15140122
van Es N, Le Gal G, Otten HM, Robin P, Piccioli A, Lecumberri R, et al. Screening for occult cancer in patients with unprovoked venous thromboembolism: a systematic review and meta-analysis of individual patient data. Ann Intern Med. 2017;167(6):410–7. https://doi.org/10.7326/M17-0868 .
doi: 10.7326/M17-0868
pubmed: 28828492
Delluc A, Antic D, Lecumberri R, Ay C, Meyer G, Carrier M. Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2017;15(10):2076–9. https://doi.org/10.1111/jth.13791 .
doi: 10.1111/jth.13791
pubmed: 28851126
Jara-Palomares L, Otero R, Jimenez D, Carrier M, Tzoran I, Brenner B, RIETE Investigators, et al. Development of a risk prediction score for occult cancer in patients with VTE. Chest. 2017;151(3):564–71. https://doi.org/10.1016/j.chest.2016.10.025 .
doi: 10.1016/j.chest.2016.10.025
pubmed: 27815153
Ihaddadene R, Corsi DJ, Lazo-Langner A, Shivakumar S, Zarychanski R, Tagalakis V, et al. Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood. 2016;127(16):2035–7. https://doi.org/10.1182/blood-2015-11-682963 .
doi: 10.1182/blood-2015-11-682963
pubmed: 26817957
pmcid: 4937205
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806–8. https://doi.org/10.1016/S0140-6736(07)61602-X .
doi: 10.1016/S0140-6736(07)61602-X
Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240(4857):1285–93. https://doi.org/10.1126/science.3287615 .
doi: 10.1126/science.3287615
pubmed: 3287615
Bertoletti L, Robin P, Jara-Palomares L, Tromeur C, Pastre J, Prevot-Bitot N, MVTEP investigators, et al. Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score. J Thromb Haemost. 2017;15(11):2184–7. https://doi.org/10.1111/jth.13842 .
doi: 10.1111/jth.13842
pubmed: 28875565
Rosell A, Lundström S, Mackman N, Wallen H, Thalin C. A clinical practice-based evaluation of the RIETE score in predicting occult cancer in patients with venous thromboembolism. J Thromb Thrombolysis. 2019;48(1):111–8. https://doi.org/10.1007/s11239-019-01822-z .
doi: 10.1007/s11239-019-01822-z
pubmed: 30739306
pmcid: 6556156
Kraaijpoel N, van Es N, Raskob GE, Büller HR, Carrier M, Zhang G, et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thromb Haemost. 2018;118(7):1270–8. https://doi.org/10.1055/s-0038-1649523 .
doi: 10.1055/s-0038-1649523
pubmed: 29864787
Mulder FI, Carrier M, van Doormaal F, Robin P, Otten HM, Salaun PY, et al. Risk scores for occult cancer in patients with unprovoked venous thromboembolism: results from an individual patient data meta-analysis. J Thromb Haemost. 2020;18(10):2622–8. https://doi.org/10.1111/jth.15001 .
doi: 10.1111/jth.15001
pubmed: 32654348
pmcid: 7590094
White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014;46(3 Suppl 1):S7–15. https://doi.org/10.1016/j.amepre.2013.10.029 .
doi: 10.1016/j.amepre.2013.10.029
pubmed: 24512933
pmcid: 4544764
Aunan JR, Cho WC, Søreide K. The biology of aging and cancer: a brief overview of shared and divergent molecular hallmarks. Aging Dis. 2017;8(5):628–42. https://doi.org/10.14336/AD.2017.0103 .
doi: 10.14336/AD.2017.0103
pubmed: 28966806
pmcid: 5614326
Berben L, Floris G, Wildiers H, Hatse S. Cancer and aging: two tightly interconnected biological processes. Cancers (Basel). 2021;13(6):1400. https://doi.org/10.3390/cancers13061400 .
doi: 10.3390/cancers13061400
pubmed: 33808654
pmcid: 8003441
Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685–705. https://doi.org/10.1146/annurev-physiol-030212-183653 .
doi: 10.1146/annurev-physiol-030212-183653
pubmed: 23140366
Barca-Hernando M, Lopez-Ruz S, Marin-Romero S, Garcia-Garcia V, Elias-Hernandez T, Otero-Candelera R, et al. Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy. Res Pract Thromb Haemost. 2023;7(2): 100115. https://doi.org/10.1016/j.rpth.2023.100115 .
doi: 10.1016/j.rpth.2023.100115
pubmed: 37063761
pmcid: 10099299
Rézig S, Mao RL, Couturaud F, Lacut K, Delluc A. Incidence of cancer after a second unprovoked venous thromboembolic event. Thromb Haemost. 2019;119(3):490–5. https://doi.org/10.1055/s-0039-1677745 .
doi: 10.1055/s-0039-1677745
pubmed: 30685873
Mrozinska S, Cieslik J, Broniatowska E, Malinowski KP, Undas A. Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P-selectin predict occult cancer after unprovoked venous thromboembolism. J Thromb Haemost. 2019;17(11):1912–22. https://doi.org/10.1111/jth.14579 .
doi: 10.1111/jth.14579
pubmed: 31323706
Sánchez-López V, Marín-Romero S, Ferrer-Galván M, Elías-Hernández T, Lobo Beristain JL, Ballaz Quincoces A, et al. Occult cancer in patients with unprovoked venous thromboembolism: a nested case-control study. Am J Clin Pathol. 2024;164:501–11. https://doi.org/10.1093/ajcp/aqad178 .
doi: 10.1093/ajcp/aqad178
Franco-Moreno A, Madroñal-Cerezo E, Muñoz-Rivas N, Torres-Macho J, Ruiz-Giardín JM, Ancos-Aracil CL. Prediction of venous thromboembolism in patients with cancer using machine learning approaches: a systematic review and meta-analysis. JCO Clin Cancer Inform. 2023;7: e2300060. https://doi.org/10.1200/CCI.23.00060 .
doi: 10.1200/CCI.23.00060
pubmed: 37616550
Muñoz AJ, Souto JC, Lecumberri R, Obispo B, Sanchez A, Aparicio J, et al. Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning. Thromb Res. 2023;228:181–8. https://doi.org/10.1016/j.thromres.2023.06.015 .
doi: 10.1016/j.thromres.2023.06.015
pubmed: 37348318